STUDY DESIGN AND METHODS: Platelets in 100%
plasma and red blood cells (RBCs) were spiked with chikungunya virus. Infectious chikungunya virus titers were measured in contaminated blood products before and after treatment with amotosalen/ultraviolet A light for platelets in 100% plasma and after treatment with amustaline/glutathione for RBCs. Viral infectivity was quantified by plaque assay.
RESULTS:
The mean chikungunya virus infectivity titers before inactivation were 6.50 log 10 plaque-forming units/ mL for platelets in 100% plasma and 7.60 log 10 plaqueforming units/mL for RBCs. No infectivity was detected after amotosalen/ultraviolet A light or amustaline/ glutathione treatment, corresponding to greater than 6.5 log 10 plaque-forming units/mL and greater than 7.1 log 10 plaque-forming units/mL of inactivation, respectively.
CONCLUSION: Robust levels of chikungunya virus inactivation were achieved for platelets in 100% plasma and for RBC components. The licensed amotosalen/ ultraviolet A light technology and the amustaline/ glutathione pathogen-reduction system under development may provide an opportunity for comprehensive mitigation of the risk of chikungunya virus transfusion-transmitted infection by plasma, platelets, and RBCs. C hikungunya virus (CHIKV) is a positive-sense, single-stranded RNA virus that belongs to the genus Alphavirus in the family Togaviriade. CHIKV infection may be symptomatic in more than 75% of cases. 1 Although the mild form of the disease is marked by self-limited fever accompanied by joint pain and swollen joints, severe outcomes, with the characteristic body-twisting arthralgia and neurologic involvement, can persist and relapse over long periods of time.
adaptation of the virus may have resulted in increased ability for A. albopictus to transmit CHIKV. 5 With reports of travel-associated infections and the spread of the mosquito vector, CHIKV has become a global public health concern. 6 CHIKV did not attract the attention of the scientific and medical community until its spread throughout the Indian Ocean islands and parts of Southern Asia and India in 2005. 3 A high proportion of severe cases was reported during the emergence of CHIKV in the Indian Ocean islands in 2005. 1 The virus spread throughout the Indian Ocean with a major two-wave, 17-month-long outbreak reported in 2005 through 2007 in Reunion Island, France, where approximately 312,500 to 757,000 inhabitants were infected, making it the most serious public health crisis in the island's history. 7 CHIKV outbreaks were also reported in 13 and has since led to over 1.7 million cases in the Americas.
14 Although CHIKV is an arbovirus mostly transmitted through mosquito bite, nonvector-borne transmission has been documented in animal models as well as in laboratory and clinical settings, with heightened concerns over the report of prolonged shedding of CHIKV in semen and urine. 15 Although several reports have documented accidental pipette/needle stick-driven infections in the laboratory setting, [16] [17] [18] in 2006, an autochthonous case was reported in metropolitan France in a health care worker who developed fever (CHIKV infection was confirmed) 3 days after probable blood exposure while caring for a CHIKV-infected patient. 19 These findings suggest a potential risk for CHIKV transfusion transmission. Indeed, viremia may develop 1 or 2 days before symptom onset; therefore, there is a risk for presymptomatic infected donors to donate blood while in the viremic phase of the infection. In addition, because 10 to 25% of infections are subclinical, the risk of donations from asymptomatic blood donors is high. [20] [21] [22] Both presymptomatic and asymptomatic viremic blood donations are of concern for the safety of the blood supply. Considering the high attack rate reported during CHIKV outbreaks resulting in 25% of the population being infected, the risk associated with presymptomatic/asymptomatic donors is further increased based on the sheer number of cases that can occur. 23, 24 Viremic donors are problematic, because CHIKV infection results in a relatively short viremic phase that generally lasts for 9 or 10 days but may peak before the development of anti-CHIKV immunoglobulin M and G antibodies 25 and is characterized by high viral loads greater than 10 8 plaque-forming units (PFU)/mL reported in infected patients, 26 with viral loads ranging from 5 3 10 2 to 1.3 3 10 8 copies/mL in blood donors identified in the acute phase of infection before seroconversion occurred. 25, 27 Therefore, CHIKV poses a threat to the blood supply, and concerns over transfusion-transmitted infection (TTI) through blood components collected from presymptomatic/asymptomatic infected donors have significantly increased throughout the world. 28 Historically, mitigation strategies to reduce the risk of CHIKV TTI have consisted of donor deferrals based on clinical presentation, which do not prevent presymptomatic or asymptomatic donors from donating. A postdonation interview ensuring that the donor remains healthy has been seen as only partially effective. With no licensed blood-screening assay commercially available, ceasing blood collection in outbreak areas and importing blood components from nonendemic areas can be an option. In addition, the use of research tests has been an important part of the immediate response. 30, 32, 38 During the Reunion Island outbreak of 2006, blood collections were stopped during the peak of the outbreak 30 and after roughly onethird of the island had been infected. However, this option is not always viable in remote areas like Reunion Island, where labile blood components like platelets cannot be imported in a timely manner. 31 To address the risk of platelet shortage, an alternative option was considered. Pathogen inactivation of platelets using amotosalen/ultraviolet A (UVA) light (Fig. 1A ) was implemented to mitigate the CHIKV TTI risk while maintaining blood availability for those requiring platelet transfusion. Based on the extent of the epidemic, 11 TTIs were predicted; however, no proven CHIKV transmissions were observed during the entire epidemic. 32 Previously conducted studies demonstrated the ability of amotosalen/UVA treatment to inactivate CHIKV in platelets resuspended in platelet-additive solution (PAS) and in plasma components, achieving inactivation of greater than 6.4 log 10 50% tissue culture infectious dose (TCID 50 )/mL and 7.6 log 10 TCID 50 /mL, respectively. 33 An alternative technology is being developed for the inactivation of pathogens in RBCs using amustaline (S-303) and glutathione (GSH) (Fig. 1B ). 34 The current study, for the first time, measured the extent of CHIKV inactivation attained in platelets in 100% plasma (PC100) and in leukocyte-reduced RBC components.
MATERIALS AND METHODS

Experimental design
Cells and viruses
CHIKV strain LR2006 OPYI (GenBank Accession number DQ443544.2) was utilized for all inactivation studies performed in platelet concentrate (PC) and RBC units. The strain was originally isolated in 2006 from a febrile patient who returned to France from Reunion. The strain was passaged five times in Vero cell culture and once in suckling mice. Seed stocks of CHIKV 2006 OPY1 strain were originally generated by the electroporation of in vitrotranscribed viral RNA in BHK-21 baby hamster kidney cells followed by an additional passage in A. albopictus C6/36 cells, as previously described. 5, 35 The virus used for both studies was titered along with control and test samples for each replicate, with average stock titers determined to be 7.91 log 10 PFU/mL and 8.70 log 10 PFU/mL for the studies conducted in RBCs and PC100, respectively. Vero76 African green monkey kidney epithelial cells were utilized for the titration of CHIKV.
Platelets, inoculation of PC units with CHIKV, sampling, and treatment process PC100 units were collected by BloodSource and at Research Blood Components from random donors and were shipped to the Biosecurity Research Institute (BRI). Donor PCs were collected the day before each experiment on either the Trima apheresis platelet-collection device (Terumo BCT) at BloodSource or the Haemonetics apheresis platelet-collection device (Haemonetics Corporation), suspended in autologous plasma in a 1-L PL2410 container, and shipped to BRI. The INTERCEPT Blood System for Platelets ( Fig. 2A ) was used for pathogen inactivation according to the manufacturer's instructions. The system comprises a processing set with 15 mL of 3 mM amotosalen, an illumination container, a compound adsorption device (CAD) container, and a 1-L storage container, as well as an illumination device that delivers UVA light (INT100; Cerus Corporation). The handling of infectious material (virus culture, infection of PCs, UVA illumination) was performed at BRI. Four PC units (Replicates 1, 2, 3, and 4) were inoculated with CHIKV and treated with amotosalen/UVA according to the following method (Fig. 3A) . Before inoculation with CHIKV, 30 mL of platelet suspension was removed from each unit, and 3.0 mL of CHIKV stock was added to each unit through a Luer lock adapter at an approximate 1:100 dilution, resulting in approximately 6 log 10 PFU/mL of CHIKV in each unit of PC100. Aliquots of stock virus were created for titration and frozen with the control and test samples. The previously removed platelet aliquot was used to rinse the Luer lock adapter line. Each CHIKVcontaminated PC100 unit was sterile-connected to the blind lead above the amotosalen container. The dosed CHIKV-inoculated PC100 units were transferred to the illumination container by gravity, and the original platelet and amotosalen containers were removed. Each PC100 unit was mixed end-over-end to ensure thorough homogenization. Pre-inactivation samples (0J Control) were removed and frozen immediately after collection. Each PC100 unit was placed into the illumination device and dosed with 3.0 J/cm 2 of UVA light. After illumination, posttreatment samples (3J Test) were removed from each PC100 unit to determine residual viral titer. The CAD step was not performed for these studies, because earlier experience indicated that viral titers are not affected by the CAD. All samples were frozen until analysis.
RBCs, inoculation of RBC units with CHIKV, sampling, and treatment process
Whole-blood citrate-phosphate-dextrose-stored units were collected the day before the experiment and processed to AS-5 RBC concentrates. Upon receipt of units at BRI, the AS-5 RBC units were weighed and adjusted to approximately 255 mL before the addition of CHIKV and were treated with the INTERCEPT Blood System for RBCs, which comprises an S-303 vial, a GSH vial, a trifurcated set with two 0.2-m filters and a blind lead, and a processing set with three containers (Fig. 2B ): a mixing bag containing a proprietary processing solution, an incubation bag, and a storage bag containing saline adenine glucose-mannitol additive solution. The handling of infectious material (virus culture, infection of RBCs, chemical inactivation) was performed at BRI Biosafety Level 3 laboratories. Four RBC units were inoculated with CHIKV, resulting in approximately 7 log 10 PFU/mL of CHIKV. The units were mixed end-over-end to ensure proper homogenization. The trifurcated filter set was sterile-connected to the mixing container on the processing set, and the CHIKVcontaminated RBC units were sterile-connected to the blind lead (Fig. 3B) . The RBC units were treated with amustaline/GSH, as described by Laughhunn and colleagues. 36 Two preinactivation samples were taken from all units: one was frozen immediately after inoculation with CHIKV and dosing with GSH, and the other was allowed to incubate at room temperature for 3 hours to mirror the treated RBC units. After removal of the control samples, the RBC units were dosed with amustaline and then transferred to the incubation container and stored at room temperature for 3 hours. At the end of the 3-hour incubation, test samples were removed to determine the level of viral reduction achieved. All samples were frozen until analysis.
Detection of infectious virus
Plaque assays were performed on Vero76 cells to determine the titer of infectious virus in all stocks of CHIKV and blood products spiked with CHIKV based on a previously described method with minor modifications. 37 Frozen CHIKV stock, control samples, and test samples were thawed and diluted in L-15 medium supplemented with 10% fetal bovine serum, 10% tryptose phosphate broth, 100 U/mL penicillin, and 100 mg/mL streptomycin (culture medium). In addition, 5 U/mL of heparin was added to the culture medium to prevent the formation of clots. Stock CHIKV and control samples were serially diluted, and the test samples were diluted 1:10 for PC100 and 1:100 for RBCs to avoid cytotoxicity associated with the blood products, which would impair the ability to detect any residual infectious virus. All titrations were performed on six-well plates previously seeded with Vero76 cells. Inocula were added to plates with confluent cell monolayers (1-mL volumes were added to 4 wells each for stock and control titrations and to 20 wells each for the test dilutions) and allowed to incubate for approximately 1 hour, with agitation every 15 minutes. At the conclusion of the 1-hour incubation, the inocula were removed, and all wells were overlaid with culture medium containing 1.5% methyl cellulose. After 5 days of incubation at 378C, titers were determined by fixing the plates with formalin and staining with 1% crystal violet solution. Plaques were enumerated for each dilution macroscopically, and viral titers were expressed as PFU/mL. For the posttreatment samples in which no infectious virus was detected, higher volumes were tested to increase the limit of detection for the assay.
RESULTS
Detection of replicative CHIKV in PC100 samples before and after inactivation
For the study conducted in PC100 samples, viral titers in preinactivation samples (control) averaged 6.5 6 0.1 log 10 PFU/mL (Table 1) . No residual virus was detected in the posttreatment samples (test), resulting in a viral titer less than 20.3 log 10 PFU/mL and an overall log reduction of greater than 6.8 6 0.1 log 10 or greater than 6.5 log 10 PFU/ mL (Table 1) . Validation studies were conducted to ensure that cytotoxicity or inhibition of infectivity was not present at the dilutions inoculated for the test and control samples due to the presence of platelets in plasma. The validation study titrations yielded the same CHIKV titers when serial dilutions were performed on platelets in plasma or culture medium, indicating that the test system did not have a detrimental impact on the quantitation of viable replicating virus.
Detection of replicative CHIKV in preinactivation and postinactivation RBC samples
For the study conducted in RBC samples, viral titers in preinactivation samples averaged 7.6 6 0.2 log 10 PFU/mL, whereas preinactivation samples incubated at room temperature for 3 hours averaged 7.4 6 0.2 log 10 PFU/mL (Table 2 ). This indicates that incubation of CHIKV in RBCs dosed with GSH did not have a detrimental impact on the virus, and any inactivation could be attributed to the effect of amustaline. No residual virus was detected in the posttreatment samples, resulting in a viral titer of less than 0.5 log 10 PFU/mL and a log reduction of greater than 7.1 6 0.2 log 10 or log 10 PFU/mL. Validation studies were conducted to ensure that cytotoxicity or inhibition of infectivity was not present at the dilutions inoculated for the test and control samples due to the presence of RBCs. The validation study titrations yielded similar CHIKV titers when serial dilutions were performed in RBCs dosed with GSH and processing solution and when dilutions were created in culture medium, indicating that the blood products and the excess of inactivated virus particles present in the test articles did not have a detrimental impact on the quantitation of viable virus. No replicative virus was detected in any postinactivation samples for both the treated RBC and PC100 units, regardless of the volume plated.
DISCUSSION
The results of our study demonstrate the robust inactivation of CHIKV in PC100 (Table 1) and RBCs (Table 2 ). The amustaline/GSH treatment and the amotosalen/UVA treatment resulted in reductions of viral titer by greater than 7.1 6 0.2 log 10 PFU/mL in RBCs and 6.5 6 0.1 log 10 PFU/mL in PCs, respectively. Based on the reported infectious titers ranging from 8.4 3 10 1 to 2.9 3 10 5 PFU/mL in asymptomatic individuals, both methods are expected to significantly reduce the risk of CHIKV TTI by blood components donated by asymptomatic donors. 24, 38 We previously reported a correlation between infectious CHIKV and genomic equivalents (GEq/mL), with an approximate ratio of GEq/mL to TCID 50 /mL calculated as 200:1. 39 Assuming this conversion and the widely accepted theoretical ratio of 0.7 between TCID 50 /mL and PFU/mL titers based on Poisson distribution (i.e., 1.0 3 10 5 TCID 50 /mL is equivalent to 7.0 3 10 4 PFU/mL; American Type Culture Collection), a log reduction greater than 9.0 log 10 GEq/mL of CHIKV RNA was achieved in PC100 samples, whereas a log reduction greater than 9.2 log 10 GEq/mL was achieved in RBCs. Our previous studies illustrated the ability of the amotosalen/UVA system to inactivate greater than 6.4 log 10 TCID 50 /mL in platelets in plasma-PAS, equating to greater than 8.7 log 10 GEq/mL of CHIKV RNA and greater than or equal to 7.6 log 10 TCID 50 / mL in plasma, corresponding to greater than 9.9 log 10 GEq/mL of CHIKV RNA (Table 3) . 33 These results are consistent with similar correlations identified in other arboviruses, such as Zika, 36 dengue 40 and West Nile viruses, 41 in which the genomic viral loads correspond from 100-fold to 1000-fold the infectivity titers observed in the same samples, as determined by comparing infectivity titers measured by cell culture assays with viral loads measured by nucleic acid amplification assays. With CHIKV and other arboviruses emerging and reemerging in various geographies, the safety of the blood supply is at stake in both endemic and nonendemic areas. Indeed, the risk associated with arbovirus outbreaks is a global concern, because transmission can occur through blood transfusions as an alternative mode of transmission, even in areas lacking arthropod vectors. CHIKV, like Zika virus, reportedly causes large-scale epidemics in which, within short periods of time, a high percentage of immunologically na€ ıve individuals can be infected. Such high attack rates have dramatic implications for patients in need of blood transfusion in endemic areas, because mitigation strategies based on donor deferral, blood screening, and discontinuing blood collections can lead to blood component shortage. 38 Although the exclusion of symptomatic individuals from the donation and postdonation self-reporting programs implemented in endemic regions can significantly reduce the incidence of transfusion transmission, the symptom-based monitoring approach was only able to identify 50% of potential viremic blood donors during the recent outbreak in the Caribbean Island of Saint Martin, where the percentage of asymptomatic infection was estimated to be 40%. 38, 42 Although the ratio of symptomatic to asymptomatic CHIKV infections varies significantly in different endemic regions, 23, 24, 43 donation from asymptomatic or presymptomatic donors can become a significant source of potential contamination for different blood products. Remarkably, only the French Blood Services have successfully implemented systematic surveillance of CHIKV RNA for platelet donors. 44 The lack of predonation screening capabilities thus has created a significant challenge in ensuring the safety of transfusions. The development of pathogen-reduction systems for all components that address the infectivity of CHIKV is a desirable and feasible approach to help maintain the safety and availability of the blood supply. The amotosalen/UVA system evaluated in this study resulted in a greater reduction of viral titers than the treatment of platelets with ultraviolet C light. 45, 46 The CHIKV inactivation reported in this study also was significantly greater than the inactivation achieved by the treatment with UV/riboflavin in platelets (2.1 log 10 ) or plasma (2.2 log 10 ). 39 Interestingly, similar ranges of approximately 2.2 to 2.5 log 10 reduction have been reported for the inactivation of other arboviruses using UV/riboflavin. 47, 48 The ability of UV/riboflavin to inactivate CHIKV was shown to be affected by the presence of plasma proteins, something not observed for the amotosalen/UVA system. 39 In conclusion, our study has successfully demonstrated that inactivation of CHIKV to the limit of detection is very efficient in PC100 units with the licensed amotosalen/UVA technology and in RBC units with the amustaline/GSH system under development. 24, 26, 27 Therefore, the application of these methods may provide an opportunity to reduce the risk of TTI during CHIKV epidemics and in endemic regions. 39 . ‡ Log titers in TCID 50 /mL were based on the assay method used for titration Tsetsarkin 2013 33 . § Inactivation based on input virus would be greater than 6.52 log 10 PFU/mL.
